Editorial: The Challenge of Psychopharmacological Treatment of Anxiety Among Youth Offspring of Parents With Bipolar Disorder

Goldstein, Benjamin I.

doi:10.1016/j.jaac.2023.11.002

Journal of the American Academy of Child & Adolescent Psych

2024

DOI: 10.1016/j.jaac.2023.11.002

|View full text |Cite

Editorial: The Challenge of Psychopharmacological Treatment of Anxiety Among Youth Offspring of Parents With Bipolar Disorder

Benjamin I. Goldstein

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Adverse event profile of lorazepam: a real-world pharmacovigilance study using the FDA adverse event reporting system database

Su,

Huang,

Chen

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

IntroductionAnxiety diagnoses have surged recently during and after the COVID-19 pandemic. Lorazepam is widely recognized for its efficacy in treatment of anxiety, as well as insomnia, etc. However, the long-term safety profile of lorazepam in extensive patient populations has not been thoroughly established.MethodsThis study aims to evaluate the potential lorazepam-associated adverse events (AEs) using data mining of the Food and Drug Administration Adverse Event Reporting System (FAERS) of the United States, seeking to provide a guidance for the future therapeutic practices.ResultsOur study revealed drug abuse, suicide attempt, sopor, delirium, and psychotic disorder were among the most prevalent AEs linked to lorazepam. In addition to common AEs, we also found that patients using lorazepam may have the risk of abnormal fat metabolism, cardiac impairment, and immunosuppression-related disorders.DiscussionIn general, our research has unveiled novel AE signals and expanded our understanding of the safety profile of lorazepam in clinical practices, providing guidance for its rational use.

show abstract

Adverse event profile of lorazepam: a real-world pharmacovigilance study using the FDA adverse event reporting system database

Su,

Huang,

Chen

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Editorial: The Challenge of Psychopharmacological Treatment of Anxiety Among Youth Offspring of Parents With Bipolar Disorder

Cited by 1 publication

References 8 publications

Adverse event profile of lorazepam: a real-world pharmacovigilance study using the FDA adverse event reporting system database

Adverse event profile of lorazepam: a real-world pharmacovigilance study using the FDA adverse event reporting system database

Contact Info

Product

Resources

About